Healthcare · Diagnostics Research · NASDAQ
| Market cap | $2.02B |
|---|---|
| Trailing P/E | 11.9 |
| Price / book | 1.4 |
| Price / sales | 3.5 |
| FCF yield | 6.3% |
| Dividend yield | — |
| Gross margin | 72.0% |
| Operating margin | 17.6% |
| Net margin | 21.8% |
| Revenue growth (YoY) | +16.0% |
| Revenue growth (3-yr annual) | +20.4% |
| EPS growth (YoY) | +73.8% |
| FCF/share growth (YoY) | +92.5% |
| Beta | 2.0 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics Research |
Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.38). Beat the EPS estimate in 4 of 4 recent quarters.
| Quarter | Reported | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3 2026 | Nov 4, 2026 | $0.51 | $0.41 | +24.4% | $151.75M |
| Q2 2026 | Jul 30, 2026 | $0.54 | $0.43 | +25.6% | $150.32M |
| Q1 2026 | May 5, 2026 | $0.52 | $0.33 | +57.6% | $139.07M |
| Q4 2025 | Feb 25, 2026 | $0.53 | $0.41 | +29.3% | $140.64M |
Median target $40.00 from 10 analysts, ranging $30.00 – $60.00.
| Ticker | Company | Market cap | P/E |
|---|---|---|---|
| TMO | Thermo Fisher Scientific | $255.19B | 27.9 |
| DHR | Danaher | $160.10B | 27.3 |
| WAT | Waters | $89.71B | 31.7 |
| IDXX | IDEXX Laboratories | $54.33B | 46.5 |
| A | Agilent Technologies | $49.44B | 28.9 |
| NTRA | Natera | $42.04B | — |
| IQV | IQVIA | $41.29B | 19.6 |
| MTD | Mettler-Toledo International | $33.93B | 36.8 |
Veracyte trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →
| Member | Chamber | Trade | Amount | Disclosed |
|---|---|---|---|---|
| Gilbert Cisneros | House | Buy | $1,001 - $15,000 | Apr 7, 2026 |
| Gilbert Cisneros | House | Sell | $1,001 - $15,000 | Dec 15, 2025 |
| Gilbert Cisneros | House | Buy | $1,001 - $15,000 | Jul 10, 2025 |
| Josh Gottheimer | House | Buy | $1,001 - $15,000 | Nov 11, 2023 |
| Josh Gottheimer | House | Sell | $1,001 - $15,000 | Oct 15, 2023 |